GNRH1 and prostate cancer: A recently published study using the SEER database has demonstrated a significantly increased risk of developing incident diabetes, coronary heart disease, myocardial infarction and sudden cardiac death in men with prostate cancer who received ADT, when compared with those who did not [26] Even short durations of LHRH agonist therapy (1–4 months) were shown to carry increased risk of incident diabetes and coronary heart disease.